This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Lexicon Pharmaceuticals' CEO Presents At Morgan Stanley Healthcare Conference (Transcript)

Stocks in this article: LXRX

Lexicon Pharmaceuticals, Inc. (LXRX)

Morgan Stanley Healthcare Conference Call

September 11, 2012, 08:00 am ET


Arthur Sands - President & CEO

Brian Zambrowicz - EVP & Chief Scientific Officer


David Friedman - Morgan Stanley


David Friedman - Morgan Stanley

Okay. Thanks everyone for joining us here today. I am David Friedman one of the biotech analysts. Up here we have the team from Lexicon; on the far side, Brian Zambrowicz, Executive Vice President and Chief Scientific Officer and then on the near side here Arthur Sands, President and CEO.

So thank you very much both of you for coming and we would love this to be as interactive as possible, so everyone please feel free to ask any questions; you can just raise your hand and we’ll get you a microphone.

So thank you all for coming. You guys have a lot going on as usual. So, may be if you want to give a couple of minute overview of the company for those who aren’t familiar and your unique approach to drug development.

Arthur Sands

Yeah, so we have five compounds in drug development, all derived from our genomic platform which I think is unique to Lexicon. That platform we developed and evolved over the last 15 years based on gene knockout technology, so all of the targets were identified starting with the human genome, but then again what’s unique and I think advantageous about our drug discovery system is that we model each of these targets in knockout before we embark on a drug discovery program.

1 of 3

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,804.80 +26.65 0.15%
S&P 500 2,070.65 +9.42 0.46%
NASDAQ 4,765.38 +16.9840 0.36%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs